Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

13.53 -0.35 (-2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Exposures Animal Testing Artificial Intelligence Product Safety
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Certara reports $106M Q1 revenue, authorizes $100M buyback, and launches a new AI-driven non-animal testing tool to support biopharma innovation. 
Via Benzinga
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies 
From Certara
Via GlobeNewswire
Earnings Scheduled For February 26, 2025
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Certara
Via Benzinga
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization
From Certara
Via GlobeNewswire
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
What Analysts Are Saying About Certara Stock
Via Benzinga
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency. 
Via Benzinga
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
Beyond The Numbers: 4 Analysts Discuss Certara Stock
Via Benzinga
Top movers in Friday's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Markets Reel As Trump's Tariffs Hit — Magnificent 7 Set To Shed Almost $700 Billion
Trump's new tariffs trigger selloff, framed as correction to trade imbalance. China faces 37% duties, EU 20%, Japan 24%. Tech stocks hit hard. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making 
From Certara
Via GlobeNewswire
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
McKemey joins Certara to accelerate growth of its strategic drug development solutions 
From Certara
Via GlobeNewswire
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Certara
Via GlobeNewswire
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Certara
Via GlobeNewswire
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list 
From Certara
Via GlobeNewswire
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Appoints John Reynders as New Independent Board Member
From Certara
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.